Group 1: ABG and Reebok - Authentic Brands Group (ABG) denies rumors of selling Reebok to Anta, stating no plans to divest the brand now or in the future [3] - Reebok, acquired by Adidas for $3.8 billion in 2006, has struggled to compete in the North American market, leading to its eventual sale to ABG for $2.5 billion in 2021 [4][5] - ABG's initial forecast for Reebok's global retail sales to reach $5 billion in 2023 has been exceeded, with a target of $10 billion by 2027 [5] Group 2: Labor Issues at Gucci - Approximately 1,000 Gucci employees in Italy threaten to strike over the refusal of parent company Kering to pay bonuses for 2022-2024 [6] - This labor dispute comes at a sensitive time for Gucci, which is facing declining sales and is under new CEO Luca de Meo's leadership [7] Group 3: Crocs Financial Struggles - Crocs' stock plummeted by 29.2% after the company projected a 9%-11% decline in Q3 revenue, marking its lowest stock price in nearly three years [8] - The company reported a nearly $500 million net loss in Q2, largely due to a $700 million goodwill impairment from its $2.5 billion acquisition of HEYDUDE [8] - Rising tariffs are expected to increase costs by $40 million in the second half of 2025, further challenging Crocs' low-cost business model [8] Group 4: Ralph Lauren's Growth - Ralph Lauren's quarterly revenue exceeded Wall Street expectations, with projected sales growth of low to mid-single digits for the fiscal year [19] - Sales in Asia and Europe saw double-digit growth, while North America grew by 8%, with China showing the highest growth at 30% [19] Group 5: Anta's Joint Venture with Musinsa - Anta has formed a joint venture with Korean e-commerce platform Musinsa, with Anta holding 40% and Musinsa 60% [22] - Musinsa aims to open over 100 stores in China by 2030, with the first store set to launch in Shanghai in Q4 of this year [22]

在资本市场的潮起潮落中，宏源药业的股价走势堪称一场令人揪心的"跳水表演"。从上市首日的破发窘境，到两年间股价从45元一路狂泻至13.7元，并且 跌势至今未止，宏源药业究竟经历了什么？这背后又隐藏着哪些不为人知的秘密呢？ 上市即破发，美梦碎成泡影 如果说上市首日破发只是噩梦的开始，那么接下来宏源药业的业绩表现，则彻底让股价踏上了雪崩之路。上市后，宏源药业的业绩随即变脸。2023年上半 年，公司归母净利润同比下滑78.51%，经营活动产生的现金流量净额同比下滑198.11%。全年来看，2023年归母净利润为8300万元至9700万元，同比下降 80.91%至77.69%。 业绩下滑的原因，一方面是公司所处行业竞争激烈。在锂电池材料领域，六氟磷酸锂销售价格持续在低位徘徊，虽然宏源药业六氟磷酸锂产销规模保持增 长，但产品售价同比大幅下降，导致盈利能力降低。另一方面，受国家集采和医保政策影响，医药终端竞争加剧，原料药市场竞争也愈发激烈。宏源药业 的甲硝唑产销量虽有增长，但产品单位售价下降幅度大于单位成本下降幅度，产品毛利下降，进而影响了公司整体盈利能力。 糟糕的业绩反映在股价上，便是一路阴跌不止。从上市首日盘中创下的4 ...